North Dakota’s bipartisan effort to make insulin more affordable offers a clear test case for how state-level prescription drug caps work in practice—and where they still fall short. Enacted in March 2025 under House Bill 1114, the law caps out-of-pocket costs for eligible insured patients at $25 for a 30-day supply of covered insulin, while providing a separate $25 reimbursement for covered delivery supplies such as syringes and pen needles.

The measure reflects growing public frustration with a healthcare system that has long charged hundreds of dollars a month for a hormone people need to survive, demonstrating that rising drug costs can bridge steep partisan divides. Still, the state’s protections do not apply to every resident with diabetes, as eligibility depends on the type of health coverage a patient carries—and insulin is only one piece of the overall cost of managing the condition.

What to know about North Dakota’s new insulin copay cap

Insulin is essential for people with Type 1 diabetes, whose bodies produce little or none of the hormone needed to regulate blood sugar, as well as for many individuals managing Type 2 diabetes. For years, steep list prices forced families across the country to pay hundreds or even thousands of dollars out of pocket each year.

The Kritzberger family in North Dakota has experienced that financial strain firsthand. Despite having health insurance, they spend $8,000 or more annually on medication, medical supplies and doctor appointments for their 17-year-old daughter, Nina, who lives with Type 1 diabetes, according to reporting from NPR and KFF Health News. Stories like theirs pushed North Dakota lawmakers to expand an earlier 2023 pilot program for state employees into broader commercial insurance protections.

How much will people with diabetes save under North Dakota’s insulin cap?

For patients whose health plans are covered by the law, limiting monthly insulin copays to $25 can translate into immediate savings. Someone who previously paid $100 per month can save up to $75 per refill, while a patient who previously paid $300 per month can save up to $275. Actual savings vary depending on a patient’s specific prescription and prior cost-sharing structure.

The protection is especially meaningful for people enrolled in high-deductible health plans, which typically require patients to spend thousands of dollars out of pocket before insurance begins covering care. Under North Dakota’s law, the $25 cap applies even before a patient meets their annual deductible.

However, capping insulin does not cap total diabetes expenses. The cap does not cover other medications, doctor visits or diabetes technology like insulin pumps and continuous glucose monitors, which often carry separate out-of-pocket charges. Nationally, KFF Health News reports that average annual out-of-pocket insulin spending for people with private insurance fell from $470 in 2018 to $220 in 2025—yet national averages still mask heavy costs for families managing complex care.

Who qualifies for North Dakota’s $25 insulin copay cap?

North Dakota’s law applies only to health plans subject to state regulatory authority, including individual marketplace plans and fully insured employer-sponsored plans bought through a commercial insurer.

Many large companies, however, operate self-funded health plans, meaning the employer pays workers’ medical claims directly rather than purchasing a policy from an insurance carrier. According to KFF, under the federal Employee Retirement Income Security Act (ERISA), self-funded plans are exempt from state insurance mandates. As a result, two neighbors living in North Dakota can face sharply different insulin prices at the pharmacy counter depending on how their employer structures its benefits.

Meanwhile, older adults and others enrolled in Medicare are covered by a separate federal protection: Medicare Part D caps monthly out-of-pocket insulin costs at $35, rather than North Dakota’s $25 state limit.

Why did North Dakota Republicans and Democrats come together to cap insulin costs?

The legislation united lawmakers who frequently clash over the government’s role in healthcare. Republican Sen. Sean Cleary co-sponsored the bill alongside Democratic Sen. Tim Mathern, who had spent years pushing for insulin affordability measures despite being one of only five Democrats in a heavily Republican Senate.

Cleary noted that lawmakers across party lines recognized the insulin market was failing patients who were still paying hundreds of dollars a month for a medication that has been commercially available for a century.

Health insurers and business groups pushed back against the mandate, arguing that capping copays for insulin users would drive up premiums for other policyholders. Blue Cross Blue Shield of North Dakota lobbyist Megan Hruby warned lawmakers that coverage mandates do not automatically make health insurance more affordable overall.

Supporters countered with data from North Dakota’s earlier insulin cap program for state employees, which lowered patient costs without triggering significant premium spikes. Republican state Rep. Carrie McLeod, who is also a diabetes educator, told lawmakers that the healthcare system had drifted too far toward financial returns, adding, “The insurance companies started out to really help people with catastrophic needs, but things have gotten out of control.” The bill ultimately passed both chambers by wide bipartisan margins.

How do high insulin prices affect people living with diabetes?

Insulin moves glucose from the bloodstream into cells for energy. Without enough insulin, blood sugar can climb to dangerous levels. When high prices force patients to delay refills, skip doses or ration their supply, they risk diabetic ketoacidosis (DKA)—a life-threatening complication that occurs when the body breaks down fat for fuel too quickly, causing acids called ketones to build up in the blood.

Even when insulin itself is more affordable, living with Type 1 diabetes requires constant preparation and backup supplies. Nina Kritzberger told KFF Health News that she routinely carries spare equipment in case her insulin pump or continuous glucose monitor malfunctions, alongside fast-acting glucose to treat sudden drops in blood sugar. While these additional supplies and devices are manageable for some households, they can still strain family budgets, even when a copay cap lowers insulin costs.

Could North Dakota’s insulin copay cap increase health insurance premiums?

Whether state copay caps push up premiums remains a central point of debate. Insurers and business associations contend that when insurers absorb a larger share of prescription costs, they recoup those expenses by raising rates across the broader risk pool.

Patient advocates and lawmakers point to North Dakota’s state employee health plan as evidence that insulin caps can be absorbed with minimal impact on monthly premiums. Still, actuaries note that long-term rate effects depend on plan design, negotiated drug rebates and the extent to which enrollees use the benefit.

How does North Dakota’s insulin cap compare with protections in other states?

North Dakota joins a growing wave of state-level action on insulin affordability. According to the American Diabetes Association, 29 states and the District of Columbia have enacted laws capping insulin copays for state-regulated commercial health plans.

Colorado passed the nation’s first insulin copay cap in 2019, initially setting the limit at $100 for a 30-day supply. Later, other states adopted stricter caps ranging from $25 to $35. The details vary widely: some states cap costs per prescription, while others cap a patient’s total 30-day supply of insulin, and only a handful extend protections to diabetes supplies or devices.

At the federal level, the Inflation Reduction Act of 2022 established the $35 monthly insulin cap for Medicare beneficiaries, leaving commercially insured patients reliant on state laws unless Congress acts.

What does North Dakota’s insulin cap mean for the future of affordable diabetes care?

North Dakota’s experience shows that personal testimony from affected families can turn prescription drug affordability into a bipartisan priority—even in conservative legislatures.

“Federal lawmakers are also considering broader protections. In 2026, bipartisan legislation called the INSULIN Act was introduced to cap insulin costs for those with private or employer-sponsored insurance at $35 per month. If enacted, it would provide coverage to some individuals who are not currently covered by Medicare’s cap,” Anne Kamwila, a healthcare policy analyst, shares with Blavity Health.

That federal push has gained momentum on Capitol Hill: the Senate version of the INSULIN Act (S. 4189) cleared the Senate Health, Education, Labor, and Pensions Committee with bipartisan support in July 2026, followed by companion legislation (H.R. 10227) introduced in the House in September.

Bottom line

North Dakota’s $25 insulin copay cap offers important financial protection to patients with eligible insurance plans, including some people who would otherwise face high costs before meeting their deductibles. However, it does not cover every insurance plan or every expense associated with diabetes, so patients should check their coverage before assuming the limit applies to them. Until a nationwide standard becomes law—and until policymakers address the high price of continuous glucose monitors, insulin pumps, and routine care—a patient’s zip code and insurance type will continue to dictate how affordable diabetes management truly is.

Frequently Asked Questions

What is the difference between Type 1 and Type 2 diabetes when it comes to insulin use?

People with Type 1 diabetes need insulin because their bodies produce little or none, while some people with Type 2 diabetes need insulin when their bodies cannot make or use enough.

What are the different types of insulin, and how do they work?

Insulin types include rapid-acting, short-acting, intermediate-acting, long-acting, and ultra-long-acting products, which differ in how quickly they begin working and how long they lower blood sugar.

What are the warning signs of low blood sugar, and how should hypoglycemia be treated?

Low blood sugar can cause shaking, sweating, hunger, dizziness, or confusion, and the CDC recommends the 15-15 rule for many people who can safely swallow: take 15 grams of fast-acting carbohydrates, wait 15 minutes, and check blood sugar again.

Citations

Levey N. Fed up with the healthcare industry, this red state capped insulin prices for patients. NPR. November 13, 2026. Accessed November 18, 2026. https://www.npr.org/2026/11/13/nx-s1-6032717/diabetes-insurance-insulin-price

Levey NN, Norman H. Fed Up With the Healthcare Industry, This Red State Capped Insulin Prices for Patients. KFF Health News. November 13, 2026. Accessed November 18, 2026. https://kffhealthnews.org/health-industry/insulin-copay-price-caps-diabetes-patients-high-costs-north-dakota-common-ground/

Pestaina K, Wallace R, Long M. The Regulation of Private Health Insurance. KFF. October 3, 2025. Accessed November 18, 2026. https://www.kff.org/patient-consumer-protections/health-policy-101-the-regulation-of-private-health-insurance/

Centers for Medicare & Medicaid Services. Insulin. Medicare.gov. Accessed November 18, 2026. https://www.medicare.gov/coverage/insulin5.American Diabetes Association. State Insulin Copay Caps | ADA. diabetes.org. Accessed November 18, 2026. https://diabetes.org/tools-resources/affordable-insulin/state-insulin-copay-caps

Sayed BA, Finegold K, Anders Olsen T, et al. Insulin Affordability and the Inflation Reduction Act: Medicare Beneficiary Savings by State and Demographics. ncbibooks. October 2, 2023. Accessed November 18, 2026. https://www.ncbi.nlm.nih.gov/books/NBK616488/